Loading...
Loading...
Ranked by Compass Score · 20 companies · Updated October 9, 2026
The most hyped names in biotech attract capital the same way a bright light attracts moths, and with similar results. By the time a genomics company is on every analyst's buy list and every retail investor's watchlist, the probability of outsized returns has already been priced down to something much less exciting. The crowded trade feels safe because everyone agrees. That consensus is usually where the opportunity ends.
The Compass Score cuts through that by running every name through eight factors simultaneously: clinical pipeline depth, balance sheet durability, management track record, patent positioning, and more. No single factor wins the argument. The score forces a broader view, and consistently surfaces companies where the fundamentals are stronger than the market price implies. That gap between what a company is worth and what it is trading at is where this kind of investing does its work.
Get our top Biotech & Genomics ideas, free
The Alexandria e-letter delivers our highest-conviction picks, earnings intelligence, and contrarian calls twice a week. Join free.
Free forever. Unsubscribe anytime. We never share your email.
Higher Compass Scores reflect where fundamentals, momentum, and forward catalysts align. Tap any company for the full breakdown.
Standout: Market Position (97/100) · Direction: Accumulate · $1.04T
Standout: Market Position (86/100) · Direction: Accumulate · $31.9B
Standout: Theme Purity (99/100) · Direction: Hold · $2.1B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $8.2B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $4.6B
Standout: Valuation (80/100) · Direction: Accumulate · $2.3B
Standout: Theme Purity (99/100) · Direction: Accumulate · $30.0B
Standout: Moat (90/100) · Direction: Accumulate · $76.1B
Standout: Theme Purity (99/100) · Direction: Accumulate · $4.9B
Standout: Revenue Growth (89/100) · Direction: Accumulate · $7.8B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $6.1B
Standout: Theme Purity (99/100) · Direction: Accumulate · $127.6B
Standout: Moat (88/100) · Direction: Accumulate · $2.5B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $2.4B
Standout: Revenue Growth (97/100) · Direction: Accumulate · $3.6B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $1.7B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $1.8B
Standout: Revenue Growth (83/100) · Direction: Hold · $1.2B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $641M
Standout: Revenue Growth (98/100) · Direction: Accumulate · $310M
By Alexandria's Compass Score, Eli Lilly and Company (NYSE:LLY) currently ranks highest among Biotech & Genomics names with a score of 92/100 (True North). Compass Scores are recomputed weekly across eight factors, so rankings shift as the fundamentals do.
Every company is scored 1-100 on eight weighted factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The composite is percentile-normalized into a Compass Score and a tier from True North to Avoid. It is a contrarian lens that rewards what the crowd overlooks rather than what is already priced in.
A high Compass Score reflects where fundamentals, momentum, and forward catalysts align. It is research, not investment advice. Use the ranking as a starting point, then read each company's full Compass Direction analysis before making any decision.
Get the contrarian edge, free
Join the Alexandria e-letter for top-rated stocks, earnings intelligence, and the take the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Compass Scores are proprietary editorial research generated by Alexandria's analysis engine from publicly available data. They are one data point among many and do not constitute investment advice or a recommendation regarding any security. Rankings update weekly and may change.